Lipids & metabolic liver disease
The Relationships Between MASLD, Extrahepatic Multimorbidity, and All-Cause Mortality in the UK Biobank Cohort
Main finding · All-cause mortalityResult — go to the resultHazard ratio 1.16 95% CI 1.13–1.19Authors' conclusion
Those with MASLD exhibited a higher prevalence of extrahepatic multimorbidity and a 16% higher rate of mortality than those without, underscoring the impact of liver steatosis on mortality and highlighting the need to target LTCs to improve outcomes and reduce health care burdens.
Study context
- Population
- UK Biobank participants; multimorbidity defined as ≥2 of 47 prespecified extrahepatic long-term conditions (LTCs)
- Participants
- 438,840 participants
- Exposure
- MASLD vs no MASLD
- MASLDn = 131,020
- Outcome
- All-cause mortality
- Follow-up
- Median 13 years
Methodological detailspopulation-based, adjusted Cox models
- Population-based
- Adjusted Cox models
Main finding
As reported in the abstract
Hazard ratio
1.16
95% CI 1.13–1.19
MASLDvs Non-MASLD
HR 1.16 (95% CI 1.13–1.19)
Observational data: associations, not effects.
Further findings
Prevalence of multimorbidity at baseline
| Outcome | MASLD | Non-MASLD |
|---|---|---|
| Mortality per additional LTC at baseline | ||
| HR | 1.30 (1.29, 1.32) | 1.38 (1.37, 1.40) |
LTCs associated with increased mortality in MASLD
- LTCs associated with increased mortality in people with MASLD, of 47
- 16
- MASLD strongly associated with several LTCs, particularly metabolic, cardiovascular, cancers, kidney, mental/behavioral and respiratory diseases
Original publication
The Relationships Between MASLD, Extrahepatic Multimorbidity, and All-Cause Mortality in the UK Biobank Cohort. J Clin Endocrinol Metab. Published 10 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →